

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

IntegraGen Reports Continued Growth During 1st Half of 2017

- **Sales of € 3.1 million, up 8%**
 - **Launch of the diagnostic activity following licensing agreement with Laboratoire CERBA**
-

Evry, France, 11 July 2017, 8h00 - IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announced its sales for the first half of 2017.

Strong growth in genomics services for clinical research and microbiology

IntegraGen's sales amounted to € 3.1 million for the year to date as of June 30, 2017, an 8% increase compared to the same time period in 2016. The genomics activities for clinical research, located at the Gustave Roussy site in Villejuif, and microbiology at the Institut Pasteur once again increased sharply totaling € 1.1 million during the first half of the year. Genomic services activity for research clients remained stable at 1.9 M € over the same period. Order intake also increased in the first half of the year, confirming the overall growth of the company's genomic services business. Additionally, the company's contract with Gustave Roussy to provide sequencing services for clinical research was renewed for a further period of three years.

Other highlights for the first half of 2017

IntegraGen has recently launched the first "beta test" of the ICE (Interpretation of Clinical Exome) software. This software tool is designed to assist with the interpretation of genomic sequencing data for clinical oncology and to optimize the treatment of affected patients by directing them towards the most appropriate treatments. Initial feedback is expected for French testers during the third quarter of 2017. The Company plans to launch the first commercial version of this software in 2018.

In February 2017 the Company successfully completed a capital increase of € 3.7 million in connection with a private placement. These funds will primarily be utilized to finance operational expenses related to the finalization of the ICE software and the launch of the miRpredX predictive diagnostic kit.

In conjunction with the release of IntegraGen's revenue figures, Bernard Courtieu, Chairman and Chief Executive Officer of IntegraGen stated, "The growth in sales the company experienced during the first half of 2017, the continued growth of our business with Gustave Roussy in Villejuif, and the launch of a test to measure miR-31-3p expression in cancer patients as a result of our licensing agreement with Laboratoire CERBA, a leading European biology laboratory, testifies to IntegraGen's development capabilities across all of its business segments. These efforts combined with other planned initiatives make us confident for the Company's future prospects."

IntegraGen will release its interim results for 2017 on September 29, 2017.

About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.0 million in 2016. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com

CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53